MCRB · Seres Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 5, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 22, 2025; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MCRB
this stock
Seres Therapeutics, Inc.
|
$46.03M | -68.7% | -95.0% | — | 3.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.30B | +7.3% | +20.8% | 20.5 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +20.2% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 22, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MCRB | +3.3% | -3.9% | -47.1% | -3.5% | -68.7% |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | +4.5% | -7.2% | -59.3% | -5.7% | -80.6% |